Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Polyps 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 44Peripheral Blood Stem Cell Transplantation 25fludarabine phosphate 24Doxorubicin 23Etoposide 22Vincristine 21Prednisone 20Whole-Body Irradiation 19Rituximab 18Filgrastim 16Brentuximab Vedotin 15Mycophenolic Acid 14Cyclosporine 14Busulfan 14Methotrexate 12Radiotherapy 11Cytarabine 11Carboplatin 10Melphalan 9Ifosfamide 9Antilymphocyte Serum 9Tacrolimus 8Methylprednisolone 8Gemcitabine 8Bortezomib 8Dexamethasone 7Vorinostat 6Everolimus 6Crizotinib 6romidepsin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Lymphoma, Large-Cell, Anaplastic × Sennosides × Clear all
NCT00001337 2025-06-22

Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
348 enrolled 15 charts
Lymphoid

Burkitt Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡